CEDARS-SINAI MEDICAL CENTER

JenaValve completed the first patient procedure for its Trilogy transcatheter heart valve system registry, JENA-VAD, within the ALIGN-AR study. The registry aims to evaluate Trilogy's safety and effectiveness in treating severe aortic regurgitation in LVAD patients. The first case was performed at Cedars-Sinai Medical Center. JenaValve, set to be acquired by Edwards, offers Trilogy commercially in Europe and expects FDA approval by late 2025.

E. Madan led experiments, data analysis, and manuscript writing. A.M.P., V.V., A.K., and P.B. contributed to experiments, data analysis, and manuscript preparation. J.W. handled biostatistical analysis and data interpretation. T.B. and D.A. focused on microscopy, data interpretation, and figure preparation. P.C.M., G.B., M.D.B., I.D., H.K., and D.O. assisted with biostatistical analysis and data interpretation. A. Gogna and A.B. helped with figure preparation and live-cell videos. M.L.P., M.Y., D.Z., S.P., S.K., K.B., P.M., I.C., E.A.F., A.K.P., S.M., C.J.P., A.L., M.N., S.C., K.G., K.C.G., and K.S.S. contributed to pathology data collection and analysis. T.F.A., E.G., A. Gustafsson, G.L., L.N., E.Y., and R.S.-F. worked on 3D scaffold and organoid experiments. K.D.P.D. assisted with PDX experiments. N.M., M.J.P., K.J.-J., and S.H. focused on exosome biology experiments. Z.S. and W.L.R. worked on multiplexing experiments. M.B. and P.J. handled FISH experiments. H.O.R., F.A.T., and R.B. contributed to MR imaging data analysis. K.G.A., J.A., G.X., G.S., and S. Singh designed and produced mAbs. S.D., C.L.d.S., A.M.F., D.T., S.R.G., K.P., G.G., G.L.W.G.R., and H.W. edited the manuscript. A.M.H., A.R., and C.L. worked on mass spec analysis. A.S. and P.B.F. provided laboratory resources and collaboration. G.M.C., Y.L., A.L.O., L.L., and A.A.T. handled CRISPR-off experiments. A.S.P., U.M., R.D., A.K.G., K.S., and D. Chelmow contributed to ovarian cancer expertise. R.P., J.K., S.R., H.R., S. Sayeed, K.P.K., D. Connolly, K.P.N., M.O.I., M.P.K., C.M., M.A., A.L.-B., D.J., K.D.M., A. Tzankov, S.B., E.A.R., and R.C.M. assisted with pathology data collection. A. Tsung and D.S. fostered clinical collaborations. J.T. provided mouse tumor models and funding. A.P.S., R.W., K.J.W., and E. Moreno helped with manuscript writing and funding. R.G. designed the study, organized collaborations, and provided overall supervision and funding.

Hyunji Kim, a breast cancer patient, is in a clinical trial for LCB84, an antibody-drug conjugate, which has stabilized her liver metastasis. Dr. Yuan Yuan describes antibody-drug conjugates as designer drugs targeting specific cancer cells. Over 150 such conjugates are in trials, with Kadcyla, Enhertu, and Trodelvy approved for breast cancer. The field offers hope for chemotherapy-resistant diseases, with ongoing research exploring various targets and payloads.

RAIDER trial compares standard whole-bladder treatment with adaptive approaches in bladder cancer, showing safe dose escalation and maintained quality of life. 345 patients across 46 centers benefit from multiple treatment plans, with encouraging outcomes in the dose-escalated adaptive arm. Challenges include quality assurance for radiotherapy technicians and questions about whole-pelvis vs. bladder-only treatment and concurrent chemotherapy.

Foundation Fighting Blindness, in partnership with ARPA-H, aims to achieve vision recovery through six whole eye transplants in humans by 2030, with a $46 million grant supporting a multi-disciplinary consortium led by the University of Colorado Anschutz Medical Campus.

Heart failure therapies are approved based on impact on patient well-being, function, or survival, with some approved solely on symptom, functional capacity, or quality of life improvements. Most trials use a composite of cardiovascular death or heart failure hospitalization (HHF) as the primary endpoint. Secondary analyses suggest non-cardiovascular hospitalizations contribute significantly to all-cause hospitalizations (ACH) in HF trials, especially in HFpEF patients. A meta-analysis found ACH reported in half of HF trials, with less than half of ACHs accounted for by HHF, indicating the importance of prespecification. The treatment effect on ACH is about half that on HHF, impacting sample size estimation. Empagliflozin trials illustrate diminished treatment effect on ACH when broadened beyond HF events. The choice between cause-specific and all-cause outcomes in HF trials should depend on the objective, with both outcomes important for comprehensive evaluation.

An AI startup’s virtual-patient technology teaches empathy to clinicians, used at Cedars-Sinai, NHS Britain, and UTMB Galveston.

Prenetics, in partnership with David Beckham, launches IM8, a health and wellness brand with two premium products: Daily Ultimate Essentials and Daily Ultimate Longevity, available at IM8health.com, shipping to 31 countries. IM8 products are clinically proven, third-party tested, and designed to support daily health and long-term vitality.

PSC genomic classifier predicts prognosis and benefits of LT-ADT in high-risk PCa, with basal subtype showing worse outcomes and greater benefit from LT-ADT, suggesting personalized ADT recommendations.